Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CONDOR: Durvalumab and Olaparib Combinations in Relapsed Stage III NSCLC
NCT05568212Phase 2Recruiting
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- May 2022
- Primary completion
- May 2026
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, olaparib in non-small cell lung cancer (NSCLC), sponsored by Fondazione Ricerca Traslazionale. Started May 2022; status: recruiting.
02
Drugs
durvalumabolaparib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05568212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05568212.